These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 12922954)

  • 1. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?
    Baeten D; Kruithof E; Van den Bosch F; Van den Bossche N; Herssens A; Mielants H; De Keyser F; Veys EM
    Ann Rheum Dis; 2003 Sep; 62(9):829-34. PubMed ID: 12922954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.
    Collamer AN; Battafarano DF
    Semin Arthritis Rheum; 2010 Dec; 40(3):233-40. PubMed ID: 20580412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rate of serious infections in spondyloarthropathy patients treated with anti-tumour necrosis factor drugs: a survey from the Italian registry GISEA.
    Atzeni F; Sarzi-Puttini P; Sebastiani M; Panetta V; Salaffi F; Iannone F; Carletto A; Foti R; Gremese E; Govoni M; Marchesoni A; Favalli E; Gorla R; Ramonda R; Ferraccioli G; Lapadula G;
    Clin Exp Rheumatol; 2019; 37(4):649-655. PubMed ID: 30767865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy.
    De Rycke L; Vandooren B; Kruithof E; De Keyser F; Veys EM; Baeten D
    Arthritis Rheum; 2005 Jul; 52(7):2146-58. PubMed ID: 15986373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab.
    Brandt J; Haibel H; Reddig J; Sieper J; Braun J
    J Rheumatol; 2002 Jan; 29(1):118-22. PubMed ID: 11824947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations.
    Generini S; Giacomelli R; Fedi R; Fulminis A; Pignone A; Frieri G; Del Rosso A; Viscido A; Galletti B; Fazzi M; Tonelli F; Matucci-Cerinic M
    Ann Rheum Dis; 2004 Dec; 63(12):1664-9. PubMed ID: 15297279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy.
    Kroesen S; Widmer AF; Tyndall A; Hasler P
    Rheumatology (Oxford); 2003 May; 42(5):617-21. PubMed ID: 12709536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New-onset psoriatic palmoplantaris pustulosis following infliximab therapy: a class effect?
    Roux CH; Brocq O; Leccia N; Giacchero D; Breuil V; Albert C; Lacour J; Perrin C; Euller-Ziegler L
    J Rheumatol; 2007 Feb; 34(2):434-7. PubMed ID: 17295430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study.
    Fouache D; Goëb V; Massy-Guillemant N; Avenel G; Bacquet-Deschryver H; Kozyreff-Meurice M; Ménard JF; Muraine M; Savoye G; Le Loët X; Tharasse C; Vittecoq O
    Rheumatology (Oxford); 2009 Jul; 48(7):761-4. PubMed ID: 19395543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment outcome of spondyloarthropathy with infliximab].
    Głowska A; Wiland P; Szechiński J
    Pol Arch Med Wewn; 2005 Jan; 113(1):42-7. PubMed ID: 16130600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy.
    Van Den Bosch F; Kruithof E; Baeten D; Herssens A; de Keyser F; Mielants H; Veys EM
    Arthritis Rheum; 2002 Mar; 46(3):755-65. PubMed ID: 11920412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Spondylarthropathies and anti-TNFalpha drugs].
    Pavy S; Allanore Y; Kahan A
    Rev Med Interne; 2005 Sep; 26(9):717-24. PubMed ID: 16154026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pustular skin lesions in patients treated with infliximab: report of two cases.
    Starmans-Kool MJ; Peeters HR; Houben HH
    Rheumatol Int; 2005 Sep; 25(7):550-2. PubMed ID: 15711788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infection and musculoskeletal conditions: Bacterial and opportunistic infections during anti-TNF therapy.
    Strangfeld A; Listing J
    Best Pract Res Clin Rheumatol; 2006 Dec; 20(6):1181-95. PubMed ID: 17127203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors.
    Exarchou SA; Voulgari PV; Markatseli TE; Zioga A; Drosos AA
    Scand J Rheumatol; 2009; 38(5):328-31. PubMed ID: 19579151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current use of biologicals for the treatment of spondyloarthropathies.
    Keyser FD; Mielants H; Veys EM
    Expert Opin Pharmacother; 2001 Jan; 2(1):85-93. PubMed ID: 11336571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists.
    Lee HH; Song IH; Friedrich M; Gauliard A; Detert J; Röwert J; Audring H; Kary S; Burmester GR; Sterry W; Worm M
    Br J Dermatol; 2007 Mar; 156(3):486-91. PubMed ID: 17300238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data.
    Delaunay C; Farrenq V; Marini-Portugal A; Cohen JD; Chevalier X; Claudepierre P
    J Rheumatol; 2005 Nov; 32(11):2183-5. PubMed ID: 16265699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy.
    Favalli EG; Varenna M; Sinigaglia L
    Clin Exp Rheumatol; 2005; 23(2):247-50. PubMed ID: 15895899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.